Skip to main content

BTIG Reaffirms Their Buy Rating on Dexcom (DXCM)

Tipranks - Tipranks - Sat Feb 21, 11:00AM CST

BTIG analyst Marie Thibault maintained a Buy rating on Dexcom on February 18 and set a price target of $85.00.

President's Day Sale - 70% Off

According to TipRanks, Thibault is an analyst with an average return of -12.6% and a 33.53% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Ceribell, Inc., and Masimo.

In addition to BTIG, Dexcom also received a Buy from Truist Financial’s Richard Newitter in a report issued on February 17. However, on February 14, TipRanks – xAI reiterated a Hold rating on Dexcom (NASDAQ: DXCM).

See today’s best-performing stocks on TipRanks >>

Based on Dexcom’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.26 billion and a net profit of $267.3 million. In comparison, last year the company earned a revenue of $1.11 billion and had a net profit of $151.7 million

Read More on DXCM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).